Sutro Biopharma (STRO) stock
STRO's Quality Score rose 2 points on Mon, Oct 5, to -7. Closed near the day's high (2 chart checks started).
Follow STRO's trial news. Pro members can get an alert when Sutro Biopharma files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for STRO, and how long its cash lasts
From Sutro Biopharma’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
The company says its cash lasts into at least the second quarter of 2028 (8-K, Aug 12).
Dilution on the horizon
- Shelf registration (S-3, filed Mar 23, 2026)
- At-the-market share sales program (424B3, filed Apr 1, 2026)
Insiders
Chief Admin. Ofcr. & GC David Pauling bought 12,504 shares on Oct 15, 2025.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why STRO beats the market
Sutro Biopharma returned +74% over the past year to the S&P 500's +17%; revenue grew 65.2% a year against its 3 peers' median of 26.9%.
2 drivers, the timeline, and the peer table, for Pro members
Why STRO scores -7
PoorTrending down, 3 of 14 checks firingWhat the Quality Score means
- +3Chart checks 3 of 14 firing right now, one point each
- −2Long-term trend below a falling 200-day average, down over two years
- Size subtracts
- Profit subtracts
- Growth subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
What's next
Expected to report Thu Nov 5, before the open
After its last 4 reports it closed -4.1% on average, higher 2 of 4 times.
What would turn STRO's score around: 9 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
STRO has 3 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1427.1
- MACD (12, 26, 9)Above signal
- 50-day average$20.03
- 200-day average$23.00
- ADX 1453.5
- Support$14.80
- Resistance$17.33
- Bollinger Bands (20, 2)Inside
- Volume0.5x
How STRO ranks in Biotech
STRO is #278 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
SRRKOpen for its score
STOKOpen for its score
SUPNOpen for its score
SYREOpen for its score
STRO3/14-7
When does STRO report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026Before open | Before open | -5.8% | -14.9% | -12.0% |
| May 14, 2026After close | After close | +14.1% | +1.4% | -20.3% |
| Mar 23, 2026After close | After close | +8.8% | +10.5% | +13.0% |
| Nov 6, 2025After close | After close | -4.5% | -13.4% | -1.4% |
About Sutro Biopharma
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of STRO's score, with the points and the reason
- All 14 checks on STRO and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on STRO
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.